Connect to other sites within the UBM Medica Network
The sodium glucose cotransporter-2 inhibitors are the newest diabetes drugs available. Have you got the basic concepts under your belt? Try these 6 questions and find out.
LEADER 2: Prelim Results Show Baseline CT Concentrations High
Early results also found an inverse relationship between serum CT levels and estimated glomerular filtration rate.
3-month HbA1c Predicts Success of GLP-1 RA Therapy
Not all patients with type 2 diabetes respond equally to GLP-1 receptor agonists. Results of a recent study suggest what to look for before you write that next Rx.
10 New FDA-Approved Endocrinology Drugs
Since June of 2014, the US FDA has approved a number of drugs for a variety of endocrine-related diseases. Here are 10 of them.
We Don't Control the Numbers
While we are increasingly evaluated on numbers—A1c, blood pressure, LDL—these parameters are largely outside of our direct control. Mr M is a case in point.
7 Important Questions on Using SGLT2 Inhibitors in Elderly Patients
There are pros and cons to using SGLT2 inhibitors in the elderly. Are you familiar with both? Find out with 7 quick multiple choice questions.
Type 2 Diabetes in a 76-Year-Old Man: Which Drug to Add On?
John is an active older man whose A1c has gone from 6.8% to 7.6% since his last follow-up visit. He refuses to get involved in any “needle business.” What’s next?
SGLT2 Inhibitor Q & A
Four questions for you to answer, four facts you need to know.
Five Top Papers From 2014 That Will Impact Your Practice
New drugs that treat stubborn illness seen often in primary care lead this group of Top 5 Papers for 2014. Type 2 diabetes, cryptogenic stroke, and hep-C are key targets.
By clicking Accept, you agree to become a member of the UBM Medica Community.